Lanosta-8,24-dien-3-one | 5539-04-8

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: Lanosta-8,24-dien-3-one
• 英文别名: (10S,13R,14R,17R)-4,4,10,13,14-pentamethyl-17-[(2R)-6-methylhept-5-en-2-yl]-1,2,5,6,7,11,12,15,16,17-decahydrocyclopenta[a]phenanthren-3-one
• CAS: 5539-04-8
• 化学式: C₃₀H₄₈O
• 分子量: 424.7
• InChiKey: OMKJDABLEGUPIE-QFKKPMMVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  8.6
• 重原子数：
  31
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  Lanosta-8,24-dien-3-one 、 臭氧 在 氩 、 crude material 、 二氯甲烷 、 水 、 magnesium sulfate 、 crude product 、 silica gel 、 ethyl acetate n-hexane 作用下， 以 二氯甲烷 为溶剂， 反应 0.62h， 以3:1 hexane/EtOAc) to afford 5 as a white solid (1.578 g, 3.958 mmol, 78%的产率得到(4R)-4-((10S,13R,14R,17R)-4,4,10,13,14-Pentamethyl-3-oxo-2,3,4,5,6,7,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanal
  参考文献：
  名称：

  Process for preparing delta-7,9(11) steroids from Ganoderma lucidum and analogs thereof

  摘要：

  本文描述了从药用蘑菇灵芝中制备鲨烷三萜和相关化合物的过程。同时还描述了治疗癌症的化合物、组合物和方法。

  公开号：

  US09376462B2

文献信息

• PROCESS FOR PREPARING DELTA-7,9(11) STEROIDS FROM GANODERMA LUCIDUM AND ANALOGS THEREOF
  申请人：Minto Robert

  公开号：US20130184244A1

  公开（公告）日：2013-07-18

  Processes for preparing lanostane triterpenes from the medicinal mushroom Ganoderma lucidum , and related compounds are described. Compounds, compositions, and methods for treating cancer are also described.

  本文介绍了从药用蘑菇灵芝中制备鲨烯三萜类化合物的过程，以及相关化合物。同时，还介绍了用于治疗癌症的化合物、组合物和方法。
• Compounds which inhibits protein prenylation ( e.g. geranylgeranyltransferase or farnesyltransferase inhibitors) for treating Parkinson's disease
  申请人：Exonhit Therapeutics SA

  公开号：EP1656931A1

  公开（公告）日：2006-05-17

  The invention relates to compounds and their uses, particularly in the pharmaceutical industry. The invention more specifically relates to new uses of compounds that inhibit the prenylation of proteins, in particular the geranylgeranyl and/or farnesyl modifications of proteins, for treating neurodegeneration involving oxidative stress and, more particularly, Parkinson's disease. The invention also relates to corresponding methods of treatment, and can be used in human subjects for preventive or curative treatment, either alone or in combination with other active agents or treatments.

  本发明涉及化合物及其用途，尤其是在制药业中的用途。本发明更具体地涉及抑制蛋白质的前酰化，特别是抑制蛋白质的香叶基和/或法呢基修饰的化合物的新用途，用于治疗涉及氧化应激的神经变性，特别是帕金森病。本发明还涉及相应的治疗方法，可用于人体的预防或治疗，可单独使用，也可与其他活性剂或治疗方法联合使用。
• COMPOUNDS WHICH INHIBITS PROTEIN PRENYLATION E.G. GERANYLGERANYLTRANSFERASE OR FARNESYLTRANSFERASE INHIBITORS FOR TREATING PARKINSON'S DISEASE
  申请人：Exonhit Therapeutics SA

  公开号：EP1811984A1

  公开（公告）日：2007-08-01
• Compounds Which Inhibits Protein Prenylation E.G. Geranylgeransferse or Farnesyltransferase Inhibitors for Treating Parkinson's Disease
  申请人：Schweighoffer Fabien

  公开号：US20080153758A1

  公开（公告）日：2008-06-26

  The invention relates to compounds and their uses, particularly in the pharmaceutical industry. The invention more specifically relates to new uses of compounds that inhibit the prenylation of proteins, in particular the geranylgeranyl and/or farnesyl modifications of proteins, for treating neurodegeneration involving oxidative stress and, more particularly, Parkinson's disease. The invention also relates to corresponding methods of treatment, and can be used in human subjects for preventive or curative treatment, either alone is or in combination with other active agents or treatments.
• US5703067A
  申请人：——

  公开号：US5703067A

  公开（公告）日：1997-12-30